1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: 33 1 47 30 94 40
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
Article first published online: 30 JUN 2004
DOI: 10.1002/hep.20257
Copyright © 2004 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Marcellin, P., Mommeja-Marin, H., Sacks, S. L., Lau, G. K. K., Sereni, D., Bronowicki, J.-P., Conway, B., Trepo, C., Blum, M. R., Yoo, B. C., Mondou, E., Sorbel, J., Snow, A., Rousseau, F. and Lee, H.-S. (2004), A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology, 40: 140–148. doi: 10.1002/hep.20257
- †
fax: 33 1 47 30 94 40
Publication History
- Issue published online: 30 JUN 2004
- Article first published online: 30 JUN 2004
- Manuscript Accepted: 4 APR 2004
- Manuscript Received: 19 AUG 2003
Funded by
- Triangle Pharmaceuticals, Inc.
- Bukwang Pharmaceuticals Ltd.
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , Normal-phase liquid chromatography coupled with electrospray ionization mass spectrometry for chiral separation and quantification of clevudine and its enantiomer in human plasma, Journal of Chromatography B, 2012, 885-886, 97
- 2, , , , Clinical and Virological Responses to Clevudine Therapy of Hepatocelluar Carcinoma Patients with Chronic Hepatitis B, Gut and Liver, 2011, 5, 1, 82
- 3, , Photochemical transformations of 5-perfluoroalkenyl uracils, Journal of Fluorine Chemistry, 2011, 132, 10, 846
- 4, , , , , , , , , , Virologic and biochemical responses to clevudine in patients with chronic HBV infection- associated cirrhosis: data at week 48, Journal of Viral Hepatitis, 2011, 18, 4Direct Link:
- 5, , , , , , , , Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy, Journal of Hepatology, 2010, 53, 2, 261
- 6, , , , , , , , , , , , , , Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B, The Korean Journal of Internal Medicine, 2010, 25, 4, 372
- 7, , , , , , , , , Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B, Journal of Korean Medical Science, 2010, 25, 5, 738
- 8
- 9, Clevudine for Chronic Hepatitis B, Infectious Diseases in Clinical Practice, 2009, 17, 4, 217
- 10, , , , , , , , , Clevudine myopathy in patients with chronic hepatitis B, Journal of Hepatology, 2009, 51, 4, 829
- 11, Les nouvelles molécules dans la prise en charge de l’hépatite chronique virale B, La Presse Médicale, 2009, 38, 5, 692
- 12, , , , , , , Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases, The Korean Journal of Hepatology, 2009, 15, 2, 179
- 13, , , , , , , , Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients, Hepatology Research, 2009, 39, 9Direct Link:
- 14, , Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B, Journal of Hepatology, 2009, 51, 4, 787
- 15, , 2′F-Arabinonucleic acids (2′F-ANA) — History, properties, and new frontiers, Canadian Journal of Chemistry, 2008, 86, 7, 641
- 16, , A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B, PharmacoEconomics, 2008, 26, 11, 937
- 17, , , , Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future, Reviews in Medical Virology, 2008, 18, 1Direct Link:
- 18, , , , Clevudine: a promising therapy for the treatment of chronic hepatitis B, Expert Opinion on Investigational Drugs, 2008, 17, 12, 1963
- 19, , , , , , , , , , , , Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2008, 27, 12Direct Link:
- 20, Données actuelles sur le traitement de l’hépatite B chronique, La Presse Médicale, 2008, 37, 2, 287
- 21, , , , Economic evaluation of chronic hepatitis B treatments in Taiwan, Journal of Gastroenterology and Hepatology, 2008, 23, 4Direct Link:
- 22, , , Fluorinated nucleosides: Synthesis and biological implication, Journal of Fluorine Chemistry, 2008, 129, 9, 743
- 23, New Drugs for Chronic Hepatitis B: A Review, American Journal of Therapeutics, 2008, 15, 2, 167
- 24, , , , , , , , , , , , , , , Supportive Role Played by Precore and PreS2 Genomic Changes in the Establishment of Lamivudine-Resistant Hepatitis B Virus, The Journal of Infectious Diseases, 2008, 198, 8, 1150
- 25, , , , , , , , The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection, The Korean Journal of Hepatology, 2008, 14, 4, 503
- 26, , , Traitement « à la carte » de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S1
- 27, , Traitement de l’hépatite B. Conduite thérapeutique, Gastroentérologie Clinique et Biologique, 2008, 32, 5, S172
- 28, , , , , Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749
- 29, , Traitement de l’hépatite chronique B : nouvelles perspectives, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S64
- 30, , , Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies, Hepatology International, 2007, 1, 2, 316
- 31, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression, Hepatology, 2007, 46, 4Direct Link:
- 32, , , , , , , , , Clevudine Therapy for 24 Weeks Further Reduced Serum Hepatitis B Virus DNA Levels and Increased ALT Normalization Rates without Emergence of Viral Breakthrough than 12 Weeks of Clevudine Therapy, Intervirology, 2007, 50, 4, 296
- 33, , , Current Therapy of Chronic Hepatitis B, Archives of Medical Research, 2007, 38, 6, 661
- 34
- 35
- 36
- 37, , New and Emerging Treatment of Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2007, 5, 3, 285
- 38, , , , , , , , , , , , , Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients, Hepatology, 2007, 46, 3Direct Link:
- 39, , The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore, Journal of Viral Hepatitis, 2007, 14, 11Direct Link:
- 40, , , , , Treatment of chronic hepatitis D, Journal of Viral Hepatitis, 2007, 14,Direct Link:
- 41, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B, Hepatology, 2007, 45, 5Direct Link:
- 42, , , , , , , , , , A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B, Hepatology, 2006, 43, 5Direct Link:
- 43, , , Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation, Bone Marrow Transplantation, 2006, 37, 6, 625
- 44, , Cellular and virological mechanisms of HBV drug resistance, Journal of Hepatology, 2006, 44, 2, 422
- 45, , , Clevudine: a potent inhibitor of hepatitis B virusin vitroandin vivo, Expert Review of Anti-infective Therapy, 2006, 4, 4, 549
- 46, , l-Nucleoside enantiomers as antivirals drugs: A mini-review, Antiviral Research, 2006, 71, 2-3, 276
- 47, , Management of chronic hepatitis B virus infection: a new era of disease control, Internal Medicine Journal, 2006, 36, 2Direct Link:
- 48, Newer antiviral agents and therapeutic approaches for chronic hepatitis b, Current Hepatitis Reports, 2006, 5, 1, 14
- 49, Nuevos fármacos para el tratamiento de la hepatitis crónica por virus B, Gastroenterología y Hepatología, 2006, 29, 54
- 50, , , Overcoming the problem of chronic hepatitis B, Drug Discovery Today: Therapeutic Strategies, 2006, 3, 2, 197
- 51, , Prise en charge de la résistance aux antiviraux dans le traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2006, 30, 10, 5
- 52, , , , Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis, Journal of Viral Hepatitis, 2006, 13, 4Direct Link:
- 53, , , , Targets of emerging therapies for viral hepatitis B and C, Expert Opinion on Therapeutic Targets, 2006, 10, 6, 833
- 54, Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies, The American Journal of Gastroenterology, 2006, 101, S1, S13
- 55
- 56, , , Treatment of chronic hepatitis B, Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3, 8, 446
- 57, Treatment of Chronic Hepatitis B in Children, Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, Supplement 1, S56
- 58, Treatment of chronic hepatitis D: New advances, old challenges, Hepatology, 2006, 44, 3Direct Link:
- 59
- 60, A review of entecavir in the treatment of chronic hepatitis B infection, Current Medical Research and Opinion, 2005, 21, 11, 1845
- 61, , Advances in chronic viral hepatitis, Current Opinion in Infectious Diseases, 2005, 18, 5, 400
- 62, , Advances in chronic viral hepatitis, Current Opinion in Internal Medicine, 2005, 4, 6, 548
- 63, , , , , , , , , Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update, Liver International, 2005, 25, 3Direct Link:
- 64, , Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs, Hepatology, 2005, 42, 6Direct Link:
- 65, , Clevudine for the treatment of chronic hepatitis B virus infection, Expert Opinion on Investigational Drugs, 2005, 14, 10, 1277
- 66, , , , , , , , Complications in treating chronic hepatitis B in patients with HIV, Expert Opinion on Pharmacotherapy, 2005, 6, 16, 2831
- 67, Disease status and therapeutic end points in hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 5
- 68
- 69, New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B, Hepatology, 2005, 41, 6Direct Link:
- 70, , Patents and development of HBV and HCV clinical treatment: from 2001 to April 2005, Expert Opinion on Therapeutic Patents, 2005, 15, 8, 1027
- 71, Peginterferon-α2afor the treatment of hepatitis B infection, Expert Opinion on Pharmacotherapy, 2005, 6, 8, 1373
- 72, , Peginterferon–α2a (40 kDa) (Pegasys®) for hepatitis B, Expert Review of Anti-infective Therapy, 2005, 3, 4, 495
- 73
- 74, , , , , , , , Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing, Journal of Clinical Virology, 2005, 34, S34
- 75, , , , , , , , Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir, Hepatology, 2005, 41, 6Direct Link:
- 76, , Treatment of antiviral therapy for chronic hepatitis B: A disease in evolution, Current Hepatitis Reports, 2005, 4, 1, 14
- 77, , , Treatment of chronic hepatitis B, Journal of Viral Hepatitis, 2005, 12, 4Direct Link:
- 78, , Update on viral hepatitis in 2004, Current Opinion in Internal Medicine, 2005, 4, 4, 359
- 79, , Drug Insight: nucleoside and nucleotide analog inhibitors for hepatitis B, Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1, 2, 90
- 80, , Emerging treatments in chronic hepatitis B, Expert Opinion on Emerging Drugs, 2004, 9, 2, 207
- 81, , , , , Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2004, 28, 12, 1215
- 82
- 83, , , Antiviral Market Overview, Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing,Direct Link:
- 84, , , Clevudine, to Treat Hepatitis B Viral Infection,Direct Link:
- 85, , , Fluorine-Containing Chiral Drugs,Direct Link: